Labs / ADME, DMPK & toxicology
ImmuVia
Cambridge, MA, United States · immuvia.com
GLP · GMP
ImmuVia develops targeted apoptosis therapeutics centered on bispecific antibodies that cluster DR5 on tumor cells to induce cell death. It works on solid tumors and leukemia, with programs for MUC16-positive cancers and a partnering platform for new tumor antigens.
They take quote requests by email.
What they offer
Discovery and preclinical development of bispecific apoptosis therapeutics
Develops tumor-targeted antibodies that trigger apoptosis through DR5 super-clustering on cancer cells.
IND-enabling development
Advances lead programs through IND-enabling studies and related de-risking work.
Partnering for new tumor targets
Offers the Cancerlysin platform for applying the same apoptosis mechanism to additional tumor antigens.
What they work on
- Modalities
- Antibody, Bispecific, ADC
- Species and models
- NHP, NSCLC, ovarian cancer, pancreatic cancer, colorectal cancer, gastric cancer, acute myeloid leukemia
- Assays and studies
- cytotoxic activity, safety characterization, in vivo efficacy
- Therapeutic areas
- NSCLC, ovarian cancer, pancreatic cancer, colorectal cancer, gastric cancer, acute myeloid leukemia
- Address
- 245 First Street, Suite 1800 Cambridge, MA 02142
Similar labs. Aurigene Pharmaceutical Services, Xcellon Biologics, Bio X Cell, Biocytogen
Found in a contract services directory. Listing built from immuvia.com. Work here? Claim this listing.